Peripheral blood T cell subset characteristics of multiple sclerosis in remission phase correlate with annualized relapse rates

Zi Ye Song, yuri nakamura, Ryo Yamasaki, Yuji Kawano, Koji Shinoda, Maimaitijiang Guzailiayi, Katsuhisa Masaki, hiroo yamaguchi, Takuya Matsushita, Jun-Ichi Kira

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Objective: A large number of disease-modifying drugs are available for multiple sclerosis (MS); however, there is no established biomarker to predict long-term disease severity and future relapses in MS. We aimed to clarify the alterations in peripheral blood T cell subsets that are associated with MS relapse and disease severity, according to cytokine production profiles in the remission phase. Methods: Blood samples collected from 29 relapsing–remitting MS patients in the remission phase and 21 healthy controls (HC) were analyzed for various cytokine-producing T cell subsets by flow cytometry. Results: MS patients in the remission phase had significantly higher percentages of interleukin (IL)-17+CD4+ T cells, IL-4+CD4+ T cells, IL-9+CD4+ T cells, interferon-γ+CD8+ T cells and IL-4+CD8+ T cells than HC (P = 0.047, P = 0.007, P = 0.026, P = 0.015 and P = 0.007, respectively). In MS, the percentages of IL-9+CD4+ T cells, IL-9+CD8+ T cells and IFN-γ+IL-17+CD8+ T cells showed a significant positive correlation with annualized relapse rates (ARR) (P = 0.011, r = 0.47, P = 0.007, r = 0.49 and P = 0.044, r = 0.38, respectively). Conclusions: In the remission phase of MS, both anti-inflammatory cytokine-producing T cells and pro-inflammatory cytokine-producing T cells are increased; however, only the percentages of pro-inflammatory cytokine-producing T cells, such as IL-9-producing CD4+ T cells, IL-9-producing CD8+ T cells and IFN-γ- and IL-17-producing CD8+ T cells, correlate with ARR. These pro-inflammatory cytokine-producing T cells in the remission phase might be candidate biomarkers for future relapses in MS patients.

元の言語英語
ページ(範囲)346-352
ページ数7
ジャーナルClinical and Experimental Neuroimmunology
7
発行部数4
DOI
出版物ステータス出版済み - 11 1 2016

Fingerprint

T-Lymphocyte Subsets
Multiple Sclerosis
Blood Cells
T-Lymphocytes
Recurrence
Interleukin-9
Cytokines
Interleukin-17
Interleukin-4
Biomarkers
Interferons
Flow Cytometry

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

これを引用

Peripheral blood T cell subset characteristics of multiple sclerosis in remission phase correlate with annualized relapse rates. / Song, Zi Ye; nakamura, yuri; Yamasaki, Ryo; Kawano, Yuji; Shinoda, Koji; Guzailiayi, Maimaitijiang; Masaki, Katsuhisa; yamaguchi, hiroo; Matsushita, Takuya; Kira, Jun-Ichi.

:: Clinical and Experimental Neuroimmunology, 巻 7, 番号 4, 01.11.2016, p. 346-352.

研究成果: ジャーナルへの寄稿記事

@article{f1fa07b0211e4e858c6ebd94221932d0,
title = "Peripheral blood T cell subset characteristics of multiple sclerosis in remission phase correlate with annualized relapse rates",
abstract = "Objective: A large number of disease-modifying drugs are available for multiple sclerosis (MS); however, there is no established biomarker to predict long-term disease severity and future relapses in MS. We aimed to clarify the alterations in peripheral blood T cell subsets that are associated with MS relapse and disease severity, according to cytokine production profiles in the remission phase. Methods: Blood samples collected from 29 relapsing–remitting MS patients in the remission phase and 21 healthy controls (HC) were analyzed for various cytokine-producing T cell subsets by flow cytometry. Results: MS patients in the remission phase had significantly higher percentages of interleukin (IL)-17+CD4+ T cells, IL-4+CD4+ T cells, IL-9+CD4+ T cells, interferon-γ+CD8+ T cells and IL-4+CD8+ T cells than HC (P = 0.047, P = 0.007, P = 0.026, P = 0.015 and P = 0.007, respectively). In MS, the percentages of IL-9+CD4+ T cells, IL-9+CD8+ T cells and IFN-γ+IL-17+CD8+ T cells showed a significant positive correlation with annualized relapse rates (ARR) (P = 0.011, r = 0.47, P = 0.007, r = 0.49 and P = 0.044, r = 0.38, respectively). Conclusions: In the remission phase of MS, both anti-inflammatory cytokine-producing T cells and pro-inflammatory cytokine-producing T cells are increased; however, only the percentages of pro-inflammatory cytokine-producing T cells, such as IL-9-producing CD4+ T cells, IL-9-producing CD8+ T cells and IFN-γ- and IL-17-producing CD8+ T cells, correlate with ARR. These pro-inflammatory cytokine-producing T cells in the remission phase might be candidate biomarkers for future relapses in MS patients.",
author = "Song, {Zi Ye} and yuri nakamura and Ryo Yamasaki and Yuji Kawano and Koji Shinoda and Maimaitijiang Guzailiayi and Katsuhisa Masaki and hiroo yamaguchi and Takuya Matsushita and Jun-Ichi Kira",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/cen3.12321",
language = "English",
volume = "7",
pages = "346--352",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Peripheral blood T cell subset characteristics of multiple sclerosis in remission phase correlate with annualized relapse rates

AU - Song, Zi Ye

AU - nakamura, yuri

AU - Yamasaki, Ryo

AU - Kawano, Yuji

AU - Shinoda, Koji

AU - Guzailiayi, Maimaitijiang

AU - Masaki, Katsuhisa

AU - yamaguchi, hiroo

AU - Matsushita, Takuya

AU - Kira, Jun-Ichi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective: A large number of disease-modifying drugs are available for multiple sclerosis (MS); however, there is no established biomarker to predict long-term disease severity and future relapses in MS. We aimed to clarify the alterations in peripheral blood T cell subsets that are associated with MS relapse and disease severity, according to cytokine production profiles in the remission phase. Methods: Blood samples collected from 29 relapsing–remitting MS patients in the remission phase and 21 healthy controls (HC) were analyzed for various cytokine-producing T cell subsets by flow cytometry. Results: MS patients in the remission phase had significantly higher percentages of interleukin (IL)-17+CD4+ T cells, IL-4+CD4+ T cells, IL-9+CD4+ T cells, interferon-γ+CD8+ T cells and IL-4+CD8+ T cells than HC (P = 0.047, P = 0.007, P = 0.026, P = 0.015 and P = 0.007, respectively). In MS, the percentages of IL-9+CD4+ T cells, IL-9+CD8+ T cells and IFN-γ+IL-17+CD8+ T cells showed a significant positive correlation with annualized relapse rates (ARR) (P = 0.011, r = 0.47, P = 0.007, r = 0.49 and P = 0.044, r = 0.38, respectively). Conclusions: In the remission phase of MS, both anti-inflammatory cytokine-producing T cells and pro-inflammatory cytokine-producing T cells are increased; however, only the percentages of pro-inflammatory cytokine-producing T cells, such as IL-9-producing CD4+ T cells, IL-9-producing CD8+ T cells and IFN-γ- and IL-17-producing CD8+ T cells, correlate with ARR. These pro-inflammatory cytokine-producing T cells in the remission phase might be candidate biomarkers for future relapses in MS patients.

AB - Objective: A large number of disease-modifying drugs are available for multiple sclerosis (MS); however, there is no established biomarker to predict long-term disease severity and future relapses in MS. We aimed to clarify the alterations in peripheral blood T cell subsets that are associated with MS relapse and disease severity, according to cytokine production profiles in the remission phase. Methods: Blood samples collected from 29 relapsing–remitting MS patients in the remission phase and 21 healthy controls (HC) were analyzed for various cytokine-producing T cell subsets by flow cytometry. Results: MS patients in the remission phase had significantly higher percentages of interleukin (IL)-17+CD4+ T cells, IL-4+CD4+ T cells, IL-9+CD4+ T cells, interferon-γ+CD8+ T cells and IL-4+CD8+ T cells than HC (P = 0.047, P = 0.007, P = 0.026, P = 0.015 and P = 0.007, respectively). In MS, the percentages of IL-9+CD4+ T cells, IL-9+CD8+ T cells and IFN-γ+IL-17+CD8+ T cells showed a significant positive correlation with annualized relapse rates (ARR) (P = 0.011, r = 0.47, P = 0.007, r = 0.49 and P = 0.044, r = 0.38, respectively). Conclusions: In the remission phase of MS, both anti-inflammatory cytokine-producing T cells and pro-inflammatory cytokine-producing T cells are increased; however, only the percentages of pro-inflammatory cytokine-producing T cells, such as IL-9-producing CD4+ T cells, IL-9-producing CD8+ T cells and IFN-γ- and IL-17-producing CD8+ T cells, correlate with ARR. These pro-inflammatory cytokine-producing T cells in the remission phase might be candidate biomarkers for future relapses in MS patients.

UR - http://www.scopus.com/inward/record.url?scp=84994234878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994234878&partnerID=8YFLogxK

U2 - 10.1111/cen3.12321

DO - 10.1111/cen3.12321

M3 - Article

VL - 7

SP - 346

EP - 352

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 4

ER -